Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZED3269
- Development stage
- Preclinical
- Lead developer
- Zedira
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZED3269 is a second-generation, reversible-acting small molecule inhibitor of tissue transglutaminase (TG2 / TGM2) developed by Zedira. It is designed with an improved oral bioavailability profile compared to earlier transglutaminase inhibitors. ZED3269 is currently in preclinical development, with rodent pharmacokinetic and efficacy data available. The drug is being investigated for the treatment of fibrotic and neoplastic diseases, including diabetic nephropathy, idiopathic pulmonary fibrosis, liver fibrosis, and mesothelioma.
- Other names
- Fibrosis program
02
Targets
TGM2 (Tissue Transglutaminase 2)
Beyond the preview
Go deeper on ZED3269.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZED3269.